Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

This study is ongoing, but not recruiting participants.
Seattle Genetics, Inc.
Hôpitaux Universitaires Henri Mondor, France
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: January 9, 2012
Last updated: February 14, 2017
Last verified: February 2017